What if the next generation of obesity medications could help patients lose nearly 30% of their body weight, dramatically improve chronic knee pain, and potentially change the way we treat several metabolic diseases at once? Now, what if those same medications eventually become available, but your insurance company decides you don’t qualify?
That is the tension playing out across obesity medicine this Monday morning. The science is advancing at an extraordinary pace, but the question patients keep asking is a relatively simple one. Will I actually be able to access these treatments, and can I afford them?
We’re tackling that question and several major developments on today’s On The Pen livestream. From new retatrutide data to the battle between oral Wegovy and Foundayo, there is plenty to talk about, and I want you to be part of the conversation.
🔴 JOIN THE CONVERSATION LIVE ON THE PEN
Watch live, ask questions in the chat, and tell us which developments could make the biggest difference in your treatment journey.
Retatrutide Is Raising the Bar, But Access Remains the Question
Eli Lilly’s investigational triple agonist, retatrutide, is generating plenty of excitement following the presentation of additional Phase 3 clinical trial data this weekend. In the TRIUMPH-4 study involving patients with obesity or overweight and painful knee osteoarthritis, participants receiving the highest dose achieved an average of 28.7% weight loss over 68 weeks, with substantial improvements in knee pain. More than one in eight retatrutide-treated participants reported no knee pain at the end of the trial.
Meanwhile, the TRIUMPH-2 trial involving patients with obesity or overweight and type 2 diabetes demonstrated average weight loss of 18.8% over 80 weeks in the primary treatment-regimen analysis at the highest dose. These are particularly impressive results in a population that has historically experienced more modest weight loss with obesity medications.
But retatrutide is not without potential drawbacks. Gastrointestinal side effects remain common, and investigators have identified additional signals involving low blood pressure and abnormal skin sensations. Importantly, retatrutide remains investigational, meaning patients cannot currently obtain it as an FDA-approved prescription medication.
The next hurdle could be insurance coverage. If payers eventually restrict access based on BMI thresholds or additional medical conditions, we could find ourselves in a familiar situation where extraordinary medical innovation remains out of reach for the patients who might benefit from it.
The GLP-1 Wars Are Heating Up
While retatrutide captures the headlines, another battle is unfolding in the rapidly expanding oral obesity medication market. Novo Nordisk’s oral Wegovy and Eli Lilly’s Foundayo are competing for patients, with early prescription tracking suggesting Wegovy currently holds a substantial lead.
We’re also keeping an eye on several developments beyond weight loss itself. New research involving semaglutide and metabolic liver disease is adding to the conversation about the broader benefits of GLP-1 therapies, while ongoing questions about CagriSema and bone health remind us why long-term safety data matter.
And in cardiovascular research, Boehringer Ingelheim’s survodutide is providing an important look at the safety of drugs that activate both GLP-1 and glucagon receptors. Its Phase 3 cardiovascular outcomes trial has demonstrated noninferiority to placebo for major cardiovascular events, a meaningful milestone for this emerging class of medicines, although it does not establish the cardiovascular safety of retatrutide itself.
With ObesityWeek beginning November 14, we’re also approaching another wave of clinical trial presentations, including additional research involving CagriSema and adolescent obesity treatment.
Patient Takeaways: Innovation Without Access Is Meaningless
For patients, the developments we’re discussing today offer several reasons to be optimistic. We’re seeing increasingly effective medications, more ways to deliver treatment, and growing evidence that addressing obesity can improve health in ways that extend far beyond a number on the scale.
But we cannot allow impressive clinical trial results to overshadow the realities of patient care. The best medication is one that a patient can tolerate, afford, access, and remain on for the long term. A treatment capable of producing 30% weight loss does little good for someone whose insurance company refuses to cover it, just as a less expensive medication offers limited value if it doesn’t adequately treat that person’s disease.
As this next generation of obesity medicine takes shape, we need more than scientific breakthroughs. We need meaningful competition, transparent pricing, sensible insurance coverage, and treatment options that recognize obesity is not a single disease with a single solution.
Join us LIVE today on On The Pen. I want to hear what you’re most excited about, what concerns you, and what you wish the pharmaceutical companies and insurance providers understood about your journey. Whether it’s retatrutide, more affordable oral medications, or the next generation of treatments, your perspective deserves to be part of this conversation.
Because patients don’t fail treatments. Treatments fail patients. And the future of obesity medicine should be built around changing that.
On The Pen is an independent obesity medicine news and patient advocacy platform. This article is for informational purposes and does not constitute medical advice.
